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Abstract
Background—Testing for high-risk human papillomavirus (HPV) infection using mailed, self-
collected samples is a promising approach to increase screening in women who do not attend 
clinic screening at recommended intervals.
Methods—To assess this intervention among high-risk women in the United States, 429 women 
without a Papanicolaou (Pap) test in 4 or more years (overdue by US guidelines) were recruited 
from the general population. Participants aged 30 to 65 years were mailed a kit to self-collect a 
cervicovaginal sample at home, return the sample by mail, and receive HPV results by telephone, 
with referral to follow-up cytological Pap testing at a local clinic. Cervicovaginal self-samples 
were collected with a Viba brush, stored in Scope mouthwash, and tested by Hybrid Capture 2. 
Data were collected in 2010 to 2011 and analyzed in 2017.
Results—Two-thirds (64%) of participants returned a self-collected sample, of whom 15% tested 
HPV DNA positive. Human papillomavirus self-test–positive women reported higher rates of 
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follow-up Pap tests (82%) than did those with self-test negative results (51%). No demographic 
differences were found in self-test return rate or HPV positivity. High acceptability was reported in 
participant surveys: most women (81%) had “mostly positive” overall thoughts about the self-test, 
and most reported being comfortable receiving the kit in the mail (99%), returning their self-
collected sample by mail (82%), and receiving their test results by telephone (97%).
Conclusions—Conducting HPV self-testing through population-based recruitment, mailed kit 
delivery and return by mail, and results delivery by telephone has the potential to reach a broad 
segment of US underscreened women.
In 2017, an estimated 12,820 women in the United States will be diagnosed as having 
invasive cervical cancer (ICC), and 4210 will die of this preventable disease.1 More than half 
of US ICC cases occur among women infrequently or never screened (“underscreened”),2 
and 15% of women report not completing Papanicolaou (Pap) testing in the preceding 3 
years—overdue by national recommendations for Pap alone.3 Barriers to screening include 
lack of health insurance, poor access to medical services,4 and embarrassment or discomfort 
with pelvic examination.5
High-risk (oncogenic) human papillomavirus (HPV) infection is the primary cause of ICC 
and high-grade precancerous lesions (cervical intraepithelial neoplasia lesions 2 or greater 
[CIN2+]).6 High-risk HPV testing improves sensitivity for the detection of CIN2+, which 
generally requires treatment.7 The US Preventive Services Task Force (USPSTF) 
recommends HPV testing in conjunction with Pap (co-testing) at 5-year intervals for women 
30 years and older.8 Primary screening by HPV testing for women 25 years and older was 
approved by US Food and Drug Administration in 20149 and will be considered by the 
USPSTF for inclusion in clinical recommendations. However, given that physician-collected 
HPV and Pap testing remain clinic based, new approaches are needed to address the larger 
problem of inadequate screening among women facing barriers to clinical services.
Self-collection of cervicovaginal samples for HPV testing, or “self-testing,” may be a viable 
option for increasing screening uptake in populations with limited access to health care.10,11 
Studies in both high- and low-resource settings have found HPV self-testing to be well 
accepted and accurate as an initial screening test, with follow-up of positive self-test results.
11–14
 Large international population-based studies and meta-analyses have found self-testing 
to be as sensitive as physician-based HPV testing and more sensitive than cytology for 
CIN2+ detection.11,14–16
In countries with national screening programs, the most appropriate target population for 
HPV self-testing is women who do not complete in-clinic screening at recommended 
intervals. Use of self-tests outside clinics (e.g., through mail) could reach patients who do 
not regularly access preventative clinical care. Studies conducted in Europe and Canada have 
shown that mailing HPV self-test kits to underscreened women (identified through national 
screening registries or medical records) increases screening completion compared with in-
clinic screening invitations.12,17–20 National screening programs in the Netherlands and 
Denmark will be offering mailed self-test kits to women who do not respond to reminders to 
complete in-clinic cervical cancer screening.21,22
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Given that there is no national screening registry in the United States, identification of 
underscreened women in the general population is a considerable challenge. US studies have 
found that women from diverse populations respond positively to HPV self-testing, although 
most studies delivered self-collection kits and provided instructions in-person to women at 
clinics,23 community centers,24,25 or their homes for immediate return to health workers.
26,27
 To our knowledge, only 2 US studies have used mailed kits for at-home HPV self-
testing.28,29 Participants in these studies were not overdue for cervical cancer screening, and 
most were younger than age 30 years, the current minimum USPSTF-recommended age for 
HPV testing.
Our study examined feasibility and acceptability of mailing as a method for the distribution 
and return of HPV self-testing kits among low-income, underscreened women. We assess 
the feasibility and acceptability among women at high risk for cervical cancer of self-
collecting cervicovaginal samples at home, returning samples by mail for HPV testing, and 
receiving HPV results by telephone. If feasible and acceptable, HPV testing by mail could 
be a powerful tool to engage women at elevated risk for developing cervical cancer.
MATERIALS AND METHODS
Sample
We recruited low-income, underscreened women in 10 North Carolina counties with 
relatively high rates of cervical cancer (Wake, Durham, Harnett, Guilford, Wayne, 
Cumberland, Robeson, Richmond, Hoke, and Scotland counties) between January 2010 and 
September 2011. Recruitment methods included distribution of flyers and posters, referral of 
callers from United Way’s 2-1-1 social assistance hotline, and direct outreach in locations 
visited by low-income women. Potential participants were screened for eligibility by calling 
a toll-free telephone hotline, staffed 24 hours by trained American Sexual Health 
Association (ASHA) personnel. Women were study eligible if they had not received a Pap 
test in the previous 4 years, lived in North Carolina, were not pregnant, were aged 30 to 65 
years, had not undergone a hysterectomy, and met one of the following income criteria: 
children qualifying for the federal school lunch program, Medicaid or Medicare Part B 
insurance, or uninsured and living at or below 200% of the federal poverty level (determined 
by household income and size). Our study population was largely unvaccinated against HPV: 
during our data collection period, only the youngest participants would have been 26 (the 
upper age limit for catch up) when HPV vaccination was recommended to female 
adolescents by the Advisory Committee on Immunization Practices in 2007.
Design
Eligible women were mailed a self-collection kit containing a brush for collecting a 
cervicovaginal sample, a vial of preservation media, simple 2-page illustrated instructions 
for sample collection, informed consent and Health Insurance Portability and Accountability 
Act authorization forms, and a prepaid mailer to return their self-collected sample for HPV 
testing. Participants were told at enrollment that the study was based at the University of 
North Carolina, although study materials were branded as “My Body, My Test.” The 
package contained contact information of local clinics providing low-cost or free Pap tests. 
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Women who did not promptly return a self-test received a reminder letter at 2 weeks, a 
reminder telephone call at 3 weeks, and a second reminder letter at 1 month. When HPV 
laboratory results were available, ASHA call center agents called participants to provide 
results. The American Sexual Health Association is a national organization that promotes 
the sexual health of individuals, families, and communities.30 Call center agents were 
extensively trained in HPV education, counseling on results, and research best practices. At 
results delivery, agents encouraged participants to obtain a clinic-based Pap test and 
provided information on where to obtain a free or low-cost Pap in their county. On this call, 
participants also completed an “acceptability” questionnaire, described later. The American 
Sexual Health Association called participants an average of 45 days later to complete a 
“follow-up” questionnaire. Women could report Pap test attendance during either 
questionnaire, or by returning a postcard with location and date of their appointment. Human 
papillomavirus self-test–positive women who did not report a Pap test received additional 
calls to improve compliance. Study participants were informed at enrollment that they would 
receive gift cards for participation: $30 for returning the self-test and completing the 
acceptability questionnaire, $10 for reporting completion of Pap testing (by postcard or 
verbally), and $5 for completing the follow-up questionnaire. Additional effort was made to 
contact participants who did not return a sample (“nonreturners”) to collect basic 
acceptability and demographic data approximately 18 months after participants had been 
sent self-test kits. University of North Carolina Institutional Review Board reviewed and 
approved the study protocol.
Measures
Sample Self-collection and Testing—Participants collected cervicovaginal samples 
using a Viba brush (Rovers Medical Devices, BV, Oss, the Netherlands) by inserting the 
brush to the top of the vaginal canal, rotating 5 times, removing the brush, then removing the 
brush head and placing it in a 10-mL vial of Scope mouthwash, an acceptable nontoxic 
preservation medium for HPV DNA testing.31 Self-collected samples were returned to study 
offices at the University of North Carolina in prepaid, preaddressed mailers. Samples were 
deidentified and shipped in weekly batches to the Cleveland Clinic laboratory (Cleveland, 
OH) for testing for high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 
using the Hybrid Capture 2 HPV test (QIAGEN Corp, Gaithersburg, MD).
Questionnaires—The acceptability questionnaire was completed immediately before 
HPV results were delivered, and assessed HPV knowledge, medical and reproductive 
history, sociodemographics, and attitudes toward completing HPV self-testing (including 
clarity of instructions, use of the brush, concerns about the test, returning the sample by 
mail, and receipt of results by telephone). The follow-up questionnaire assessed completion 
of in-clinic “follow-up” Pap test and attitudes toward Pap testing, which are being published 
separately. The nonreturner questionnaire assessed demographics; reasons for not returning 
the self-test; overall thoughts, likes, and dislikes regarding the self-test; and “follow-up” Pap 
test completion since study enrollment. Participants could report completion of a follow-up 
Pap test on any of the questionnaires.
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Statistical Analyses
We assessed completion of self-test and follow-up in-clinic Pap testing and predictors of 
self-test sample return and HPV positivity. Predictors of self-test return (Table 1) and 
differences in study completion and HPV status by age (Table 2) were assessed by Fisher 
exact tests that allow for small sample sizes. Unadjusted P values are reported. The final 
population for assessment of HPV positivity included women who returned a self-collected 
sample (“returners”) and completed informed consent (275; 64% of eligible), and excluded 
participants with inconclusive HPV self-test results (n = 4) or samples that leaked in transit 
(n = 6). Descriptive analyses were performed for measures of acceptability (Table 3) and 
study completion (Fig. 1). Acceptability measures were assessed in those who returned a 
self-test and completed the acceptability questionnaire (227; 83% of returners). Logistic 
regression was used to estimate age-adjusted odds ratios for associations with self-test HPV 
positivity in 216 participants who received a conclusive (positive or negative) HPV self-test 
result and completed the acceptability questionnaire. Multivariable analysis adjusting for 
age, insurance status, self-reported smoking, and HIV status was conducted to assess 
predictors of HPV positivity among 216 women with conclusive self-test HPV results who 
completed the acceptability questionnaire (Table 4). Data analyses were completed in 2017 
using SAS statistical software version 9.4 (Cary, NC).
RESULTS
Participants
Of 892 women screened for eligibility, 429 (48%) were study eligible and mailed a self-
collection kit (Fig. 1). The median age of these 429 women was 42 years (range, 30–65 
years; missing 2), and one-fifth lived in rural areas (21%; Table 1). Of 255 women who 
completed the acceptability questionnaire or nonresponder questionnaire, most had less than 
a high school education (61%), were unmarried (73%), and were uninsured (67%; data not 
shown). More than half of participants who returned self-collected samples were black 
(55%). All participants reported no Pap test in the 4 years before study enrollment. Median 
time since last Pap was 5 years (range, 4 years to never). A total of 4 women (2%; data not 
shown) reported that they had never received a Pap test.
Self-Test, Questionnaire, and Pap Test Completion
Of 429 women who were sent a self-test kit, almost two-thirds (64%) returned a self-
collected sample, and 83% of those women completed the acceptability questionnaire (Fig. 
1). Of 154 nonreturners, 3 completed the acceptability questionnaire (2%) and 27 (18%) 
completed the nonreturner questionnaire. Among women who returned a sample, the 
acceptability questionnaire was completed by 79% of women 30 to 45 years of age and 88% 
of women 45 years and older. Among these women, the follow-up questionnaire was 
completed by 58% of women 30 to 45 years of age and 71% of women 45 years and older. 
There were no differences in demographic characteristics or in overall thoughts about self-
testing between women who did and did not return a sample (Table 1).
The proportion of women reporting a follow-up Pap test was similar for those who returned 
a sample and completed the follow-up questionnaire and those who did not return a sample 
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and completed the nonreturner questionnaire (55% and 48%, respectively; Fig. 1). Older 
women seemed to report Pap test more frequently than did younger women, although 
differences were not statistically significant (62% for 45–64 years vs. 49% for 30–44 years, 
P = 0.13; Table 2). Women who tested HPV positive on their self-test reported a higher rate 
of follow-up in-clinic Pap test completion compared with HPV-negative women (82% vs. 
51%, P < 0.01). This difference was statistically significant among women 45 years and 
older (91% vs. 58%, P < 0.05), but not in younger women (73% vs. 44%, P < 0.11).
Participants’ Attitudes and Opinions Regarding the Self-test
Acceptability of mailed, at-home HPV self-testing was very high among the 227 participants 
who returned a self-test and completed the acceptability questionnaire (Table 2). Most 
participants (81%) reported mostly positive thoughts about the HPV self-test. Almost all 
participants reported being comfortable receiving the kit in the mail (99%) and receiving test 
results by telephone (97%). A large majority (82%) were comfortable returning their sample 
by mail. Most women (92%) reported willingness to pay for the kit, with 48% willing to pay 
$25 or more.
Among 27 participants completing the nonreturner questionnaire (of 154 who did not return 
a sample), the most commonly reported reasons for nonreturn were misplacing the kit (6; 
22%), being too busy (4; 15%), going to the doctor instead (2; 7%), and leaving town for an 
extended period (2; 7%) (data not shown). Reasons reported by only 1 woman each were 
house fire, pregnancy, “family problems,” “just forgot,” and concern that the study “would 
do something” to her. Seven participants (26%) did not remember why or could not provide 
a specific reason.
HPV Self-Test Results
Of 262 women who returned the self-collected sample and had conclusive results, HPV 
positivity was 14.9%. Only 10 samples (3.6% of returned) were invalid: 6 leaked in transit 
and 4 had inconclusive laboratory results. There were no differences in HPV positivity when 
stratified by age (30–44 vs. 45–65 years; Table 3). Bivariate analysis of predictors of HPV 
positivity found higher positivity among women with Medicaid, women HIV positive by 
self-report, and smokers (data not shown). No association was found with age, urbanicity, 
race, income, educational level, marital status, time since last Pap test, Internet use, religious 
affiliation, age at first intercourse, parity, literacy, or current use of contraception. No factors 
for high-risk HPV positivity remained statistically significant in the multivariable analysis 
adjusting for age, insurance status, self-reported smoking, and HIV status as estimates were 
relatively imprecise (Table 4).
DISCUSSION
This study of 429 women in North Carolina is, to our knowledge, the first US study to 
conduct HPV testing using mailed home-based self-collection kits for cervical cancer 
screening among infrequently screened women. High acceptability indicates that self-
collection could be a viable approach to increase screening among this hard-to-reach, high-
risk population. No sociodemographic differences were found in self-test return, indicating 
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that women at particularly high risk for developing ICC, such as black and rural women, 
may equally benefit from a self-collection intervention. Most participants with positive HPV 
self-test results completed a follow-up Pap test, an important finding given that screening by 
HPV self-testing can only prevent ICC if HPV-positive women attend a health care facility 
for follow-up diagnostics and treatment, if indicated.
Findings of high acceptability of mailed self-collection are consistent with international 
studies that found that most women were willing to receive the self-test by mail, would 
complete self-testing again, found self-collection easy, and would recommend the self-test to 
a friend.13,20,32 Our self-test return rate by mail of 64% in this US population was in the 
middle of the range of rates observed in international studies, which have varied widely by 
study design and setting (from 8% to 93%).11,20,33–37 Our high rates of reported Pap test 
completion among HPV self-test–positive participants (82%) are consistent with other 
mailed self-test studies that achieved 41% to 91% completion of follow-up screening among 
HPV-positive women.17,18,32,34–40 Additional research is needed to track completion of 
follow-up diagnostics and treatment among HPV self-test–positive women to 
comprehensively assess impact on ICC prevention.
Our study design aimed to approximate a scalable model for increasing coverage among 
infrequently screened women by incorporating HPV self-testing into a screening program. 
Several well-conducted US studies have implemented HPV self-testing through community 
health workers and other direct-interaction approaches.23–27,41 Direct one-to-one 
engagement has many strengths, but requires considerable personnel time and effort. Our 
approach has the potential to require fewer resources per woman screened. We recruited 
most participants through population-based advertising, with a relatively lower personnel 
burden than that in direct recruitment and potential to reach women who might be missed by 
medical records review.
Furthermore, we delivered kits with illustrated instructions by mail, with personal assistance 
available as needed by telephone, rather than providing face-to-face kit delivery, coaching, 
and training. Participants also requested kits and received HPV results by telephone with 
highly trained agents at the ASHA call center, leveraging an existing resource while still 
providing high-quality test result delivery and counseling. The nonresearch components of 
the intervention requiring staff time were recruitment, preparation and mailing of kits and 
letters, laboratory testing, and delivering results, for which multiple call attempts were 
sometimes required. Exact time spent on these components is not available for the present 
study, but is being collected for a current trial of self-collection. In real-world 
implementation, reminder letters and calls could be automated, further reducing personnel 
time burden. It is also notable that HPV testing requires considerably less laboratory 
personnel time and training than cytology. Identification and recruitment of participants, on 
the other hand, was labor intensive, although it is impossible to know whether aversion to 
participation in a research study was a barrier. In future implementation, distribution of kits 
could be done via general advertising, placement in pharmacies, or through medical records 
review.
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Limitations
In terms of study limitations, self-selection into the study could have resulted in a sample of 
women with higher-than-average positive attitudes toward at-home self-testing and relatively 
higher motivation to complete cervical cancer screening. However, this approach allowed us 
to engage hundreds of women from the general population who may not have been reached 
through alternative approaches requiring a priori knowledge of screening status. Offering 
financial incentives for self-test return may have resulted in higher reported completion 
rates, although it likely improved our ability to get feedback from women toward self-
collection or cervical cancer screening more generally. Low response rate among self-test 
nonreturners limits our ability to assess reasons for nonreturn, although feedback from the 
30 nonreturners reached did not reveal any major concerns regarding the self-test process 
itself. P values should be interpreted with caution because of multiple testing and small 
sample sizes in some comparisons but can be used to begin to understand differences in 
groups. Relying on self-report also limited our ability to assess Pap test completion in 
participants lost to follow-up, and providing an incentive for Pap completion may have 
motivated overreport. Data were collected several years before analysis; however, we are 
unaware of any developments or events in recent years that are likely to have affected our 
key measures by influencing attitudes in the general population toward HPV testing or self-
testing more broadly.
Our study could have been strengthened by assessing self-test sample sufficiency (i.e., β-
globin testing), although prior studies found high β-globin positivity (97.7%–99.7%) in 
mailed, self-collected samples with the Viba brush.36,39 Given that we did not systematically 
obtain data on cytology or histology clinical end points, we were unable to assess the 
sensitivity of home-based HPV self-collection for high-grade cervical detection. Study 
design also did not permit assessment of intervention efficacy at increasing screening 
uptake. Future research among under-screened women in the United States will focus on 
validating results of mailed HPV self-testing against clinical HPV and cytology results, and 
on evaluating whether offering mailed HPV self-testing increases screening completion in 
this higher-risk underscreened population.
Our findings have several key programmatic implications. Delivery of self-test kit by mail 
and delivery of HPV results by telephone were well accepted by almost all participants—
approaches that are largely scalable. Providing patients with the option to return their 
samples by dropping them at a pharmacy, clinic, or laboratory location could provide a more 
acceptable option for the one-fifth of participants who were uncomfortable returning the 
sample by mail. Some self-collected samples (2.2%) leaked in transit. Revisions to the 
instructions emphasizing that women firmly tighten the vial greatly reduced leakage in our 
current research phases. Current research into “dry” self-collection using retractable brush 
heads or cards also seeks to reduce damage to samples in transit.42,43 Finally, most 
participants reported that they would pay for the self-test kit, indicating that there could be a 
market for the self-test kit. However, only 48% indicated willingness to pay more than $25, 
suggesting that lower pricing options, insurance coverage, and/or subsidies would be 
necessary to make the kit attainable to low-income, uninsured women. Feasibility of a 
widespread self-testing intervention is continually improving owing to considerable 
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advancements in HPV diagnostics resulting in higher sensitivity and specificity for high-
grade lesion detection, and relatively lower future costs per test.44,45
CONCLUSIONS
In conclusion, conducting home-based self-collection for HPV testing was feasible and 
highly acceptable for a sample of high-risk women recruited by advertising and outreach 
from the general population in the US South. Future studies in a US setting should evaluate 
the effect of a mailed HPV self-testing compared with standard of care, or to an evidence-
based practice for increasing screening in underscreened women. Our findings contribute to 
growing evidence that HPV self-testing has the potential to be a powerful tool to engage 
women at the highest risk for developing cervical cancer into preventative screening.
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Figure 1. 
Participant flow diagram. AQ indicates acceptability questionnaire; FQ, follow-up 
questionnaire. *Six samples leaked in transit; 3 samples could not be run due to incomplete 
consent forms. †Not all who started FQ completed it. ‡Two non-returner questionnaire 
respondents also completed AQ.
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TABLE 1
Characteristics of Participants Who Did (n = 275) and Did Not (n = 154) Return a Mailed HPV Self-Test
All Participants, n (%)* Returned Self-test, n (%) Did Not Return Self-Test, n (%) P†
Age ≥45 y 174 (40.7) 117 (42.7) 57 (37.3) 0.30
Rural 90 (21.1) 59 (21.5) 31 (20.1) 0.81
Black 160 (55.3) 145 (55.3) 15 (55.6) 1.00
≤High school education 147 (61.3) 132 (62.0) 15 (55.6) 0.54
Not married 174 (72.8) 153 (72.2) 21 (77.8) 0.65
Thoughts about self-test mostly positive 175 (81.2) 160 (80.8) 15 (83.3) 0.41
*Numerators shown. Denominator varies depending on whether the question was asked at enrollment (denominator for age and rural, n = 429), on a 
form returned with the self-test (denominator for race, n = 303), or during the acceptability or nonreturner questionnaire (denominator for 
education, marital status, thoughts about self-test; n = 255). Missing values are as follows: age (n = 2), race (n = 14), education (n = 15), marital 
status (n = 16), and thoughts on self-test (n = 39).
†
Difference between women who did and did not return the self-test examined using Fisher’s exact test.
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TABLE 2
Attitudes Toward the Self-Test Among Participants Who Returned a Self-test and Completed the Acceptability 
Questionnaire
n (%)
Overall thoughts about the self-test
 Mostly positive 160 (81)
 Neutral 34 (17)
 Mostly negative 4 (2)
 Refused/don’t know/missing 29
Comfortable receiving the self-test kit in the mail*
 Yes 210 (99)
 No 3 (1)
 Refused/don’t know/missing 14
Comfortable returning self-test sample by mail*
 Yes 172 (82)
 No 38 (18)
 Refused/don’t know/missing 17
Comfortable receiving self-test results by telephone*
 Yes 203 (97)
 No 6 (3)
 Refused/don’t know/missing 18
Willing to pay for self-test
 Would not pay for test 18 (9)
 <$25 87 (43)
 $25–$49 51 (25)
 ≥$50 47 (23)
 Refused/don’t know/missing 24
*
Response scales:
Did you feel comfortable receiving the self-test kit in the mail? Yes/No.
Did you feel uncomfortable sending back your sample in the mail? Yes/No.
I am comfortable getting self-test results by telephone. Strongly agree/ somewhat agree/somewhat disagree/strongly disagree.
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TABLE 3
HPV Self-Test Return, Laboratory Results, and Pap Test Completion, Overall and Stratified by Age
Total 30–44 y, n (%) 45–65 y, n (%) P
Enrolled (eligible and mailed a self-test kit)* 427 253/427 (59.3) 174/427 (40.8)
Returned a home self-test by mail 274/427 (64.2) 157/253 (62.1) 117/174 (67.2) 0.31†
HPV test results among women who returned a self-test‡
 HPV positive 38/261 (14.6)‡ 23/148 (15.5) 15/113 (13.3) 0.72†
 HPV negative 223/261 (85.4)‡ 125/148 (84.5) 98/113 (86.7)
 Inconclusive/leaked sample 10/274 (3.6)§ 6/157 (3.8) 4/113 (3.5)
Reported a clinic-based Pap test at follow-up questionnaire¶ 80/145 (55.2) 35/72 (48.6) 45/73 (61.6) 0.13†
 HPV positive 18/22 (81.8) 8/11 (72.7) 10/11 (90.9)
 HPV negative 61/119 (51.3) 26/59 (44.1) 35/60 (58.3)
P < 0.01|| P = 0.11|| P < 0.05||
HPV positivity 95% confidence intervals: total, 14.9 (10.8–19.7); 30–44 years, 15.5 (10.1–22.4); 45–65 years, 13.3 (7.6–20.9).
*
Excludes 2 participants who were aged 30 to 65 years but did not report specific age.
†P values using Fisher’s exact test for difference in reported Pap test attendance in women younger than 45 years compared with those at least 45 
years old.
‡
n with result over n of valid test results. Inconclusive results excluded from calculation of percentages.
§
Includes 4 inconclusive lab results and 6 samples that leaked in transit. Not included in calculation of positive and negative result percentages. An 
additional 3 samples could not be run because of incomplete consent forms.
¶
n reporting Pap over n completing follow-up questionnaire. Reliable data on follow-up to Pap test were not available from women who did not 
complete the follow-up questionnaire.
||P value using Fisher’s exact test for difference in follow-up Pap test between HPV-positive and HPV-negative women within age category.
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TABLE 4
Multivariable Associations Between Participant Characteristics and Self-Test HPV Positivity Among 216 
Infrequently Screened Women*
Characteristic Total n* HPV Positivity, % Odds Ratio Adjusted for Age† (95% CI)
Age, y
 30–44 116 15 Ref.
 ≥45 100 14 1.01 (0.45–2.28)
Health insurance
 Uninsured 143 12 Ref.
 Medicaid 49 25 1.84 (0.76–4.47)
 Military/Blue Cross/other 16 13 1.05 (0.21–5.18)
 Missing 8
Smoking
 Smoker 110 19 1.88 (0.81–4.34)
 Nonsmoker 102 10 Ref.
 Don’t know/ missing 4
Self-report of HIV positivity
 Yes 13 39 2.93 (0.82–10.40)
 No 198 13 Ref.
 Missing 5
Ref. indicates referent group.
*
Participants who returned a self-sample, had a valid HPV result, and responded to the acceptability questionnaire.
†Adjusted for age using categorical variable: 30–44 versus at least 45 years of age, and all other variables in the table.
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